Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

Autor: Kohli, Anita, Osinusi, Anuoluwapo, Sims, Zayani, Nelson, Amy, Meissner, Eric G, Barrett, Lisa L, Bon, Dimitra, Marti, Miriam M, Silk, Rachel, Kotb, Colleen, Gross, Chloe, Jolley, Tim A, Sidharthan, Sreetha, Petersen, Tess, Townsend, Kerry, Egerson, D'Andrea, Kapoor, Rama, Spurlin, Emily, Sneller, Michael, Proschan, Michael, Herrmann, Eva, Kwan, Richard, Teferi, Gebeyehu, Talwani, Rohit, Diaz, Gabbie, Kleiner, David E, Wood, Brad J, Chavez, Jose, Abbott, Stephen, Symonds, William T, Subramanian, G Mani, Pang, Phillip S, McHutchison, John, Polis, Michael A, Fauci, Anthony S, Masur, Henry, Kottilil, Shyam

Publikováno v: In The Lancet 21-27 March 2015 385(9973):1107-1113

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Autor: Lawitz, Eric, Sulkowski, Mark S, Ghalib, Reem, Rodriguez-Torres, Maribel, Younossi, Zobair M, Corregidor, Ana, DeJesus, Edwin, Pearlman, Brian, Rabinovitz, Mordechai, Gitlin, Norman, Lim, Joseph K, Pockros, Paul J, Scott, John D, Fevery, Bart, Lambrecht, Tom, Ouwerkerk-Mahadevan, Sivi, Callewaert, Katleen, Symonds, William T, Picchio, Gaston, Lindsay, Karen L, Beumont, Maria, Jacobson, Ira M

Publikováno v: In The Lancet 15-21 November 2014 384(9956):1756-1765

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Autor: Lawitz, Eric, Lalezari, Jay P, Hassanein, Tarek, Kowdley, Kris V, Poordad, Fred F, Sheikh, Aasim M, Afdhal, Nezam H, Bernstein, David E, DeJesus, Edwin, Freilich, Bradley, Nelson, David R, Dieterich, Douglas T, Jacobson, Ira M, Jensen, Donald, Abrams, Gary A, Darling, Jama M, Rodriguez-Torres, Maribel, Reddy, K Rajender, Sulkowski, Mark S, Bzowej, Natalie H, Hyland, Robert H, Mo, Hongmei, Lin, Ming, Mader, Michael, Hindes, Robert, Albanis, Efsevia, Symonds, William T, Berrey, Michelle M, Muir, Andrew

Publikováno v: In The Lancet Infectious Diseases May 2013 13(5):401-408

Sofosbuvir and ribavirin in HCV genotypes 2 and 3

Autor: Zeuzem, Stefan, Dusheiko, Geoffrey, Salupere, Riina, Mangia, Alessandra, Flisiak, Robert, Hyland, Robert H., Illeperuma, Ari, Svarovskaia, Evguenia, Brainard, Diana M., Symonds, William T., Subramanian, G.Mani, McHutchison, John G., Weiland, Ola, Reesink, Hendrik W, Ferenci, Peter, Hézode, Christophe, Esteban, Rafael, Forns, Xavier, VALENCE Investigators.

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2014, 370 (21), pp.1993-2001. ⟨10.1056/NEJMoa1316145⟩
Dipòsit Digital de la UB
Universidad de Barcelona
New England journal of medicine, 370(21), 1993-2001. Massachussetts Medical Society
New England Journal of Medicine, 370(21), 1993-2001
Recercat. Dipósit de la Recerca de Catalunya
instname

none 17 si BACKGROUND: In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33b56ca9b3d4869cd3b79dd045e059bb
http://hdl.handle.net/11577/3041122

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.